Vanc Pharmaceuticals Responds to Canagen Compensation Claim

Pharmaceutical Investing

Vanc Pharmaceuticals responded to a demand letter released by Canagen Pharmaceuticals, in which they claim compensation of $510,000 from Vanc.

Vanc Pharmaceuticals (TSXV:VANC; OTCQB:NUVPF) responded to a demand letter released by Canagen Pharmaceuticals, in which they claim compensation of $510,000 from Vanc.
As quoted in the press release:

Vanc believes that the claims are wholly without merit, and intends to vigorously defend its position if an action is commenced. Vanc is issuing this news release only because Canagen took the extraordinary step of making public the delivery of its demand letter, and not because Vanc believes the allegations are material.
Vanc also announced today that it has delivered a formal demand to Mr. Mo Aziz and Canagen that they immediately and unqualifiedly publicly and prominently retract and apologize for their wrongful allegations and all other statements that disparage Vanc and its management. Vanc also demanded that no further disparagement of Vanc or its management take place.

Click here to read the full press release.

vanc pharmaceuticals Pharmaceutical Investing